Latest News and Press Releases
GlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.
www.globenewswire.comHere’s a concise update on ibogaine, based on recent reporting.
-
Texas initiatives: Several articles from 2025 highlight Texas lawmakers proposing and then passing substantial funding for FDA-approved ibogaine clinical trials, including a $50 million state-backed initiative to support such trials for addiction, PTSD, and TBI. This marks one of the largest public efforts to advance psychedelic therapies in the U.S. and signals a potential pathway toward formal clinical evaluation and regulatory approval in the future.[2][6][7]
-
Legislative and policy context: The Texas program aims to attract private investment, retain some intellectual property rights, and accelerate collaboration between public funds and private partners, with veterans’ advocacy cited as a key driver in the policy push. These developments underscore a shift toward legitimizing ibogaine research despite federal scheduling and ongoing safety considerations.[4][2]
-
U.S. safety and legal status: Ibogaine remains illegal to import and use in the United States, and there have been legal cases and reports connected to unregulated use, underscoring the importance of supervised, FDA-approved trials to establish safety and efficacy. Media coverage emphasizes both potential therapeutic promise and significant regulatory hurdles.[3][5][9]
-
Related research and clinical signals: Stanford and other institutions have published findings suggesting ibogaine may influence neuroplasticity and mood-related symptoms in veterans with traumatic brain injuries and PTSD, fueling cautious optimism about its therapeutic potential while acknowledging the need for rigorous trials.[7]
-
Public-facing portrayals: News reports and explainer pieces describe ibogaine's promise for addiction treatment and the logistical reality that access is still largely through clinics abroad or unregulated settings, contributing to ongoing debates about risk, benefit, and policy reform.[9][4]
If you’d like, I can pull the most recent dates and extract key quotes from specific sources, or summarize the regulatory status and timeline for Texas’ ibogaine initiatives in a compact digest. Additionally, I can provide a brief annotated bibliography with links to the major articles.